German vaccine maker CureVac surges almost 250% in Nasdaq debut
Shares of German biotech company CureVac, which is developing a leading coronavirus vaccine candidate, rocketed Friday in its first day of trading in New York after raising more than $200 million in an initial public offering.
Aug 15, 2020
0
4
